Zacks Research Weighs in on Iovance Biotherapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Zacks Research reduced their Q1 2025 earnings estimates for shares of Iovance Biotherapeutics in a note issued to investors on Wednesday, July 17th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn ($0.22) per share for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.35) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.59) EPS.

A number of other research analysts have also weighed in on IOVA. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, June 28th. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a research report on Friday, July 12th. Finally, JMP Securities decreased their price objective on Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating for the company in a report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $24.45.

Iovance Biotherapeutics Trading Up 4.3 %

NASDAQ IOVA opened at $8.69 on Monday. The company has a market cap of $2.43 billion, a P/E ratio of -4.83 and a beta of 0.63. The company has a fifty day simple moving average of $8.62 and a 200 day simple moving average of $10.86. Iovance Biotherapeutics has a 12-month low of $3.21 and a 12-month high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.03. Iovance Biotherapeutics had a negative return on equity of 71.45% and a negative net margin of 23,615.70%. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.99 million. During the same quarter in the prior year, the company earned ($0.50) earnings per share. The company’s quarterly revenue was up 71400.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. ORG Partners LLC purchased a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $32,000. Quadrant Capital Group LLC increased its holdings in Iovance Biotherapeutics by 1,227.8% during the fourth quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock worth $41,000 after buying an additional 4,678 shares during the last quarter. Fidelis Capital Partners LLC bought a new stake in Iovance Biotherapeutics in the first quarter worth about $87,000. Nisa Investment Advisors LLC boosted its stake in Iovance Biotherapeutics by 284.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 5,577 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in Iovance Biotherapeutics by 256.6% in the fourth quarter. Signaturefd LLC now owns 8,723 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 6,277 shares during the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.